View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
May 30, 2011

NLX-P101 Proven Effective Against Parkinson’s

Neurologix has announced efficacy results from the Phase II clinical trial of gene therapy agent NLX-P101, used for the treatment of Parkinson's disease. The trial included 45 subjects with moderate to advanced Parkinson's disease and demonstrated that treatment with NLX-P101 improved

By cms admin

Neurologix has announced efficacy results from the Phase II clinical trial of gene therapy agent NLX-P101, used for the treatment of Parkinson’s disease.

The trial included 45 subjects with moderate to advanced Parkinson’s disease and demonstrated that treatment with NLX-P101 improved the primary motor symptoms of Parkinson’s disease in patients.

Neurologix scientific co-founder Matthew J During said the results demonstrated that treatment with gene therapy agent showed the clinically meaningful improvement and durability over the long-term.

Parkinson’s disease is a progressive and debilitating neurodegenerative disorder that affects the control of bodily movement.

NLX-P101 modulates the activity of the STN, which is overactive in patients with Parkinson’s disease, by restoring GABA, a neurotransmitter important in STN function.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU